Suggested remit: To appraise the clinical and cost effectiveness of atezolizumab plus bevacizumab within its marketing authorisation for adjuvant treatment of resected or ablated hepatocellular carcinoma (HCC) at high risk of recurrence.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6148

Email enquiries


Key events during the development of the guidance:

Date Update
15 January 2024 - 12 February 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6148
08 February 2024 Following a regulatory update from the company NICE will stop the scope consultation and rearrange the scoping exercise for a later date. The appraisal is now anticipated to begin late November 2024, with an anticipated evidence submission deadline to NICE of early February 2025, when we will write to you about how to get involved.
15 January 2024 In progress. Scoping commencing
16 June 2022 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual